ReviewThe Lancet regional health. Western Pacific2024
Antimicrobial resistance in China across human, animal, and environment sectors - a review of policy documents using a governance framework.
Review in The Lancet regional health. Western Pacific, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Livestock immunomodulators as alternatives to antimicrobials - a roadmap for the fight against drug resistance.BMC veterinary research · 2026Review
- Lung microbiota-mediated biotransformation of mogroside preserves pulmonary barrier integrity and attenuates PMNPJ biofilms and microbiomes · 2026Article
- China's nationwide antimicrobial resistance surveillance networks: a systematic analysis from One Health perspective.The Lancet regional health. Western Pacific · 2026Review
- Evaluation of antimicrobial resistance governance across 193 countries to inform the 2026 Global Action Plan update.Nature medicine · 2026Article
- Climate change and antimicrobial resistance in the Western Pacific: a mixed-methods systematic analysis.The Lancet regional health. Western Pacific · 2026Article
- Amikacin-eravacycline combination mediates the synergistic elimination of carbapenem-resistant pathogens via in vitro and in vivo metabolic reprogramming.PLoS pathogens · 2026Article
- Impact of a Pharmacist-Led Grid-Based Stewardship Program on the Association Between Antimicrobial Use and Resistance: A 7.5-Year Interrupted Time-Series Analysis in a Chinese Tertiary Hospital.Infection and drug resistance · 2026Article
- Area-level socioeconomic status inequalities shape patterns of antimicrobial resistance in China, 2014-2023: a Bayesian spatiotemporal modelling analysis.The Lancet regional health. Western Pacific · 2025Article
- Barriers and facilitators of the implementation for the antimicrobial Social Norm Feedback (SNF) intervention strategy in primary care institutions: a qualitative study based on the Consolidated Framework for Implementation Research (CFIR).Antimicrobial resistance and infection control · 2025Article
- Article
- Comparative effectiveness of monotherapy vs. combination therapy for postoperative central nervous system infections in neurosurgical patients: a retrospective cohort study.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses a multifaceted threat to the human, animal, and environment sectors. In response, China has formulated a series of policies since the 2000s. Thus far, there has been no comprehensive assessment of these policy documents. This study aims to review the content of AMR policy documents at the national level using a governance framework covering three areas:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.